Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, semaglutide is still being compounded by licensed 503A pharmacies as of 2024. The FDA has maintained oversight of compounding practices while allowing pharmacies to prepare GLP-1 formulations for patient use, though regulatory scrutiny around quality and sterility remains ongoing and varies by state.

For patients considering compounded semaglutide, understanding the current regulatory landscape and how individual factors—including genetic predispositions and metabolic biomarkers—may influence treatment response can help inform a more personalized discussion with a healthcare provider about whether this option aligns with their clinical needs.

Current Status of 503A Compounded Semaglutide in 2024

Licensed 503A pharmacies continue to compound semaglutide under pharmacy compounding regulations. These facilities must follow USP Chapter <797> guidelines for sterile injectable preparation, including environmental controls, personnel training, and quality assurance. State pharmacy boards maintain independent oversight, creating variability in supply and availability by region.

The FDA has not issued a blanket ban on compounded GLP-1 agents, though it has increased scrutiny on compounding practices to address safety concerns. Patients considering compounded semaglutide should verify that their pharmacy is properly licensed and maintains documented quality control measures.

How Supply Chain Stability Compares Across GLP-1 Options

Compounded semaglutide availability differs from branded alternatives in terms of supply chain predictability, regulatory pathways, and quality oversight mechanisms. The table below outlines key distinctions to consider when evaluating treatment continuity and reliability.

Treatment Type Supply Predictability Regulatory Oversight Cost Range Quality Assurance
Compounded Semaglutide (503A) Variable by pharmacy; state-dependent regulations State pharmacy boards + FDA oversight $149/mo USP <797> compliance required; varies by facility
Branded Semaglutide (Ozempic) Established distribution network FDA-approved drug; manufacturer QA Higher out-of-pocket Consistent manufacturing standards
Compounded Tirzepatide (503A) Emerging availability; developing supply State pharmacy boards + FDA oversight $249/mo USP <797> compliance required
Oral Compounded Semaglutide Growing availability State pharmacy boards + FDA oversight From $249/mo USP <795> (non-sterile) guidelines

Biomarkers and Genetic Factors That May Inform Semaglutide Candidacy

Individual responses to semaglutide vary based on genetic polymorphisms affecting GLP-1 receptor signaling, appetite regulation, and metabolic pathways. Key genetic variants—including GLP1R rs6923761 and FTO rs9939609—can help reveal predispositions in how a patient's body processes glucose and responds to satiety signals, though genetics alone do not determine medication response.

Biomarkers such as fasting glucose, HbA1c, insulin resistance indices, and inflammatory markers can provide additional context for provider decision-making. When combined with genetic predisposition data, these markers may help create a more complete clinical picture to guide treatment selection and dosing strategies.

Safety Considerations and Who Should Consult a Provider First

Compounded semaglutide carries the same contraindications and safety considerations as branded formulations: history of medullary thyroid carcinoma, personal or family history of Multiple Endocrine Neoplasia type 2, pregnancy, pancreatitis risk, or severe renal/hepatic impairment require careful medical evaluation. A qualified healthcare provider should assess individual risk factors before initiation.

Patients considering compounded semaglutide should also discuss potential side effects—nausea, vomiting, constipation, and rare GI complications—and ensure the pharmacy has documented sterility testing and potency verification. Having an established relationship with a provider who monitors treatment progress and adjusts dosing as needed is essential for safe, effective use.

How PlexusDx Supports a More Personalized Approach

PlexusDx offers the Precision Peptide Genetic Test, which analyzes key variants in GLP-1 receptor signaling (GLP1R rs6923761), glucose-fructose metabolism (FTO rs9939609), and melanocortin-4 receptor pathways (MC4R rs17782313) to reveal predispositions in peptide-based treatment response. This test may help provide context for why certain patients experience different outcomes with compounded semaglutide, supporting more informed conversations between patients and their healthcare providers.

The genetic test results should be interpreted with a qualified healthcare provider and do not predict exact medication response or guarantee treatment success. Instead, they reveal predispositions in specific genetic pathways relevant to GLP-1 metabolism and appetite regulation, which can complement clinical assessment and help guide treatment selection.

For patients considering compounded semaglutide through PlexusDx, integrating genetic predisposition data with other clinical biomarkers and medical history can support a more comprehensive evaluation of whether this option aligns with individual health goals. This precision-wellness approach prioritizes personalized decision-making alongside professional medical oversight.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves